BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 22524260)

  • 1. Diagnostic frequency, response to therapy, and long-term prognosis among horses and ponies with pituitary par intermedia dysfunction, 1993-2004.
    Rohrbach BW; Stafford JR; Clermont RS; Reed SM; Schott HC; Andrews FM
    J Vet Intern Med; 2012; 26(4):1027-34. PubMed ID: 22524260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adrenocorticotropin concentration following administration of thyrotropin-releasing hormone in healthy horses and those with pituitary pars intermedia dysfunction and pituitary gland hyperplasia.
    Beech J; Boston R; Lindborg S; Russell GE
    J Am Vet Med Assoc; 2007 Aug; 231(3):417-26. PubMed ID: 17669045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BEVA primary care clinical guidelines: Diagnosis and management of equine pituitary pars intermedia dysfunction.
    Menzies-Gow NJ; Banse HE; Duff A; Hart N; Ireland JL; Knowles EJ; McFarlane D; Rendle D
    Equine Vet J; 2024 Mar; 56(2):220-242. PubMed ID: 37795557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between hyperinsulinaemia and laminitis severity at the time of pituitary pars intermedia dysfunction diagnosis.
    Tadros EM; Fowlie JG; Refsal KR; Marteniuk J; Schott HC
    Equine Vet J; 2019 Jan; 51(1):52-56. PubMed ID: 29761574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Equine pituitary pars intermedia dysfunction.
    McFarlane D
    Vet Clin North Am Equine Pract; 2011 Apr; 27(1):93-113. PubMed ID: 21392656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence, risk factors and clinical signs predictive for equine pituitary pars intermedia dysfunction in aged horses.
    McGowan TW; Pinchbeck GP; McGowan CM
    Equine Vet J; 2013 Jan; 45(1):74-9. PubMed ID: 22594955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Equine pituitary pars intermedia dysfunction: Identifying research priorities for diagnosis, treatment and prognosis through a priority setting partnership.
    Tatum RC; McGowan CM; Dean RS; Ireland JL
    PLoS One; 2021; 16(1):e0244784. PubMed ID: 33395695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lamellar pathology in horses with pituitary pars intermedia dysfunction.
    Karikoski NP; Patterson-Kane JC; Singer ER; McFarlane D; McGowan CM
    Equine Vet J; 2016 Jul; 48(4):472-8. PubMed ID: 25869529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokine dysregulation in aged horses and horses with pituitary pars intermedia dysfunction.
    McFarlane D; Holbrook TC
    J Vet Intern Med; 2008; 22(2):436-42. PubMed ID: 18371032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case series of equine pituitary pars intermedia dysfunction in a tropical climate.
    Spelta CW; Axon JE
    Aust Vet J; 2012 Nov; 90(11):451-6. PubMed ID: 23106327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma fructosamine concentrations in horses with pituitary pars intermedia dysfunction with and without laminitis.
    Knowles EJ; Menzies-Gow NJ; Mair TS
    Equine Vet J; 2014 Mar; 46(2):249-51. PubMed ID: 23663105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurement of cortisol concentration in the tears of horses and ponies with pituitary pars intermedia dysfunction.
    Hart KA; Kitchings KM; Kimura S; Norton NA; Myrna KE
    Am J Vet Res; 2016 Nov; 77(11):1236-1244. PubMed ID: 27805438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of adrenocorticotrophic hormone as a potential biomarker of pituitary pars intermedia dysfunction in horses.
    Lee ZY; Zylstra R; Haritou SJ
    Vet J; 2010 Jul; 185(1):58-61. PubMed ID: 20537574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computed tomographic findings in the pituitary gland and brain of horses with pituitary pars intermedia dysfunction.
    Pease AP; Schott HC; Howey EB; Patterson JS
    J Vet Intern Med; 2011; 25(5):1144-51. PubMed ID: 21985144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the effects of age and pituitary pars intermedia dysfunction on corneal sensitivity in horses.
    Miller C; Utter ML; Beech J
    Am J Vet Res; 2013 Jul; 74(7):1030-5. PubMed ID: 23802675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circannual variation in plasma adrenocorticotropic hormone concentrations in the UK in normal horses and ponies, and those with pituitary pars intermedia dysfunction.
    Copas VE; Durham AE
    Equine Vet J; 2012 Jul; 44(4):440-3. PubMed ID: 21848531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of suspected pituitary pars intermedia dysfunction in horses with laminitis.
    Donaldson MT; Jorgensen AJ; Beech J
    J Am Vet Med Assoc; 2004 Apr; 224(7):1123-7. PubMed ID: 15074858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of rhythms of secretion and repeatability of plasma adrenocorticotropic hormone concentrations in healthy horses and horses with pituitary pars intermedia dysfunction.
    Rendle DI; Litchfield E; Heller J; Hughes KJ
    Equine Vet J; 2014 Jan; 46(1):113-7. PubMed ID: 23742059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with survival, laminitis and insulin dysregulation in horses diagnosed with equine pituitary pars intermedia dysfunction.
    Horn R; Bamford NJ; Afonso T; Sutherland M; Buckerfield J; Tan RHH; Secombe CJ; Stewart AJ; Bertin FR
    Equine Vet J; 2019 Jul; 51(4):440-445. PubMed ID: 30417404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of cortisol and ACTH responses after administration of thyrotropin releasing hormone in normal horses and those with pituitary pars intermedia dysfunction.
    Beech J; Boston R; Lindborg S
    J Vet Intern Med; 2011; 25(6):1431-8. PubMed ID: 22092639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.